Larimar Therapeutics’ $80.5 Million Shares Offering

Troutman Pepper advised Larimar Therapeutics, Inc. on the deal.Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, has…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now